BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Advancell Announces Promising Phase I/IIa Results with Acadra(R) in CLL


2/15/2011 10:30:19 AM

BARCELONA, Spain, February 15th, 2011. ADVANCELL, an emerging biopharmaceutical company, today announced positive results from a Phase I/IIa clinical study conducted with Acadra® in Chronic Lymphocytic Leukemia (CLL) patients resistant/refractory to current therapies. The company also announced promising non-clinical in vivo results with Acadra® in Multiple Myeloma (MM), Mantle Cell Lymphoma (MCL) and other lymphoproliferative disorders. Synergism of Acadra® in combination with current treatment in these indications has been demonstrated.

The Phase I/IIa multi-center dose-escalation study was designed to assess the safety, efficacy and pharmacokinetics of Acadra® in CLL patients with refractory or relapsed disease.

The results of this study demonstrated that Acadra® has an acceptable safety and tolerability profile at doses that induce reduction in the leukemic tumor burden. The study patient population included patients with relapsed or refractory CLL who had received a minimum of one prior line of treatment including either a fludarabine or an alkylator-based regimen (median number of prior treatments was 5). The study was conducted in two parts and enrolled twenty-four patients in cohorts of 3 patients each.

In part I, Acadra® was administered as a single dose with the aim to find the Optimal Biological dose (OBD), defined as the dose of Acadra® that generated the maximum exposure to the active metabolite ZMP with no Dose Limiting Toxicities (DLTs). Acadra® 315 mg/kg was the dose limiting toxicity (DLT) dose with one patient having a DLT of Tumour Lysis Syndrome that resolved with appropriate treatment. Saturation of the metabolism of Acadra® to ZMP occurred at 210 mg/kg. Thus, the OBD was declared as 210 mg/kg and this was the dose used for multiple Acadra® administrations in part IIa of the study. In part II, patients received up to 5 doses of Acadra®.

Please, find attached some more information

Marta Melgosa apple tree communications Assaonadors, 31 (Pral. 1ª) 08003 Barcelona Tel. + 34 93 318 46 69 Móv. + 34 665 527 130 Fax. +34 93 268 09 28



Read at BioSpace.com

Advancell
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES